Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Otonomy Inc    OTIC

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
17.2(c) 19.45(c) 19.35(c) 18.85(c) 18.75 Last
170 469 601 915 123 799 134 312 208 697 Volume
+1.78% +13.08% -0.51% -2.58% -0.53% Change
More quotes
Financials ($)
Sales 2017 1,98 M
EBIT 2017 -103 M
Net income 2017 -102 M
Finance 2017 17,2 M
Yield 2017 -
Sales 2018 11,4 M
EBIT 2018 -97,7 M
Net income 2018 -97,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 280x
Capi. / Sales2018 50,2x
Capitalization 571 M
More Financials
Company
Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.The firm's portfolio includes therapeutics for diseases and disorders of the ear such as otitis media, acute otitis externa, balance disorders, Ménière's disease, tinnitus, cisplatin-induced hearing... 
More about the company
Surperformance© ratings of Otonomy Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OTONOMY INC
08/03 OTONOMY, INC. : Results of Operations and Financial Condition, Financial Stateme..
08/03 Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate ..
08/03 OTONOMY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
08/03 OTONOMY, INC. (NASDAQ : OTIC) Files An 8-K Results of Operations and Financial C..
08/03 OTONOMY INC : Investor Network: Otonomy, Inc. to Host Earnings Call
07/27 Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate..
07/19 OTONOMY : Announces FDA Acceptance of OTIPRIO Supplemental New Drug Application ..
07/18 Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Applicatio..
06/23 OTONOMY, INC. (NASDAQ : OTIC) Files An 8-K Submission of Matters to a Vote of Se..
06/23 OTONOMY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08:46aOtonomy upgraded by Zacks Investment Research to hold.  
08/16Q2 #Earnings Wrap-Up, Remaining Q3 Milestones In Focus $INSM $OTIC $ALNY $ZYN.. 
08/15Q2 #Earnings Wrap-Up, Remaining Q3 Milestones In Focus $INSM $OTIC $ALNY $ZYN.. 
08/15Healthcare - Top 5 Gainers / Losers as of 11:00 am  
08/15JPMorgan likes Otonomy, sees almost 50% upside; shares ahead 11%  
More tweets
Qtime:11
News from SeekingAlpha
08/16 BIOTECH FORUM DAILY DIGEST : Revisiting Bellicum Pharmaceuticals
08/15 Midday Gainers / Losers
08/15 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
08/15 JPMorgan likes Otonomy, sees almost 50% upside; shares ahead 11%
08/03 Otonomy's (OTIC) CEO David Weber on Q2 2017 Results - Earnings Call Transcrip..
Chart OTONOMY INC
Duration : Period :
Otonomy Inc Technical Analysis Chart | OTIC | US68906L1052 | 4-Traders
Technical analysis trends OTONOMY INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 40,0 $
Spread / Average Target 112%
EPS Revisions
Managers
NameTitle
David A. Weber President, Chief Executive Officer & Director
Jay B. Lichter Chairman
Paul E. Cayer CFO, Chief Business & Principal Accounting Officer
Robert Michael Savel Chief Technical Officer
Dean Hakanson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OTONOMY INC18.55%571
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450